The study includes Rochester Epidemiology Project data from 7,044 adult stroke survivors collected between January 2000 and June 2022, according to a Nov. 11 news release from the American Heart Association.
Rochester, Minn.-based Mayo Clinic researchers analyzed the effect GLP-1s and SGLT2s medications had on stroke survivors’ risk of a second stroke, heart attack or death.
FDA approved medications included in the study were GLP-1s liraglutide, semaglutide and tirzepatide, and SGLT2s canagliflozin, dapagliflozin, empagliflozin and ertugliflozin.
Here are five things to know from the study:
- Adults who took either a GLP-1 or an SGLT2 had a 74% lower risk of death and an 84% lower risk of heart attack.
- Adults who took an SGLT2 had a 67% lower risk of having a subsequent stroke.
- The death rate among stroke survivors who took either a GLP-1 or an SGLT2 was 11.8%, compared to 54% among patients who did not take either medication.
- The heart attack rate among stroke survivors who took either a GLP-1 or an SGLT2 was 1.5%, compared to 6.1% among patients who did not take either medication.
- The rate of second stroke was approximately 6% among stroke survivors regardless of whether they took a GLP-1 or an SGLT2 medication.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
